Roivant Sciences Ltd. (ROIV) Discusses $2.25 Billion Global Settlement Resolving COVID Vaccine Patent Litigation Transcript
Source: SeekingAlpha
2026-03-04 05:22:18 ET
Roivant Sciences Ltd. (ROIV) Discusses $2.25 Billion Global Settlement Resolving COVID Vaccine Patent Litigation March 3, 2026 4:45 PM EST...
Read the full article on Seeking Alpha
For further details see:
Roivant Sciences Ltd. (ROIV) Discusses $2.25 Billion Global Settlement Resolving COVID Vaccine Patent Litigation Transcript
Roivant Sciences Ltd.
NASDAQ: ROIV
ROIV Trading
2.19% G/L:
$29.385 Last:
2,105,383 Volume:
$29.625 Open:
ROIV Latest News
March 04, 2026 11:42:41 pm
BlackBarn Capital Builds Warby Parker Stake as the Direct-to-Consumer Eyewear Leader Expands Nationwide
March 03, 2026 04:15:00 pm
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
March 03, 2026 04:15:00 pm
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
ROIV Stock Data
$19,574,426,097
449,460,314
0.77%
170
N/A
Biotechnology & Life Sciences
Healthcare
GB
London
